Carcinoembryonic Antigen Market Growth Rate, Specification
and Emerging Countries Forecasts Till 2022
“The market is expected to witness significant growth in the coming few years
owing to various key attributes such as growing incidence of cancer and
technological advancement regarding the development of novel biomarkers.”
Industry Insights
The Global Carcinoembryonic Antigen (Cea) Market is expected to reach USD 2.56 Billion by 2022, which is
anticipated to grow at a CAGR of more than 6.6% during the forecast period. The market is expected to witness
significant growth in the coming few years owing to various key attributes such as growing incidence of cancer
and technological advancement regarding the development of novel biomarkers. According to WHO estimates
in 2015, globally cancer is the second leading cause of death with over 8.8 million deaths. On the basis of the
Age-Standardized rate of incidence, there are approximately 205 new cases of cancer for every 100,000 men
and nearly 165 new cases of cancer for every 100,000 females in the world. Carcinoembryonic antigens are the
most cost effective technique for the preclinical detection of illness.
Technological advancements pertaining to proteomics, which include protein bioinformatics, mass
spectroscopy, protein labelling, imaging, and array based approaches, is one of the crucial factors expected to
fuel up the market growth. Development of new biomarkers and various immunological techniques such as
radioimmunoassay that can be used with carcinoembryonic antigen (CEA) for detection of various types of
cancers, and thus also propel the market growth. For instance, the development of tumor markers, which is
used in combination with CEA for detection of colorectal cancer.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/carcinoembryonic-antigen-cea-market/request-sample